68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT | NCT02481726 | Trialant
CompletedInterventionalPhase 1Phase 2Updated Jun 25, 2015
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT
ClinicalTrials.gov ID
NCT02481726
Lead Sponsor
Xijing HospitalOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1Phase 2
Enrollment
31Actual
Last Update Posted
Jun 25, 2015Estimated
Start Date
Mar 2014
Primary Completion Date
Oct 2014Actual
Brief Summary
Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.
Lung Cancer
Lung Tuberculosis
68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must be able to provide a written informed consent
Males and females, ≥18 years old.
The definite diagnosis of lung cancer was established by pre-operational bronchoscopic or puncture biopsy or the definite diagnosis of lung tuberculomas was established on the basis of positive sputum culture examinations and confirmed by follow-up.
Without any treatment or resection surgury.
All the biopsies are done at least 10 days before PET/CT scans.
Evaluation of cardiac function.
Exclusion Criteria:
Females planning to bear a child recently or with childbearing potential；
Known severe allergy or hypersensitivity to IV radiographic contrast；
Inability to lie still for the entire imaging time because of cough, pain, etc.
Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc.
Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.